TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma

Summary

This study investigates the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with the immune agent nivolumab compared to TACE alone for treating hepatocellular carcinoma (HCC). The study aims to determine if the combination therapy can more effectively inhibit tumor angiogenesis, improve clinical benefit rates, and prolong survival, while maintaining a high safety profile.

Timeline

Start

2021-10-01

Primary completion

2022-11-01

Completion

2023-12-31

Drugs

Indications